Concepts (161)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Glioblastoma | 18 | 2025 | 330 | 4.770 |
Why?
|
| Brain Neoplasms | 23 | 2025 | 1215 | 4.260 |
Why?
|
| Neoplasm Recurrence, Local | 7 | 2025 | 1143 | 1.530 |
Why?
|
| Glioma | 4 | 2022 | 491 | 1.490 |
Why?
|
| Isocitrate Dehydrogenase | 4 | 2025 | 76 | 1.430 |
Why?
|
| Astrocytoma | 2 | 2022 | 99 | 1.430 |
Why?
|
| Meningeal Neoplasms | 6 | 2024 | 185 | 1.210 |
Why?
|
| Clinical Trials as Topic | 5 | 2019 | 1090 | 0.700 |
Why?
|
| Hyperostosis Frontalis Interna | 1 | 2020 | 3 | 0.700 |
Why?
|
| Venous Thromboembolism | 2 | 2021 | 166 | 0.700 |
Why?
|
| Meningioma | 4 | 2024 | 120 | 0.650 |
Why?
|
| Somatosensory Cortex | 1 | 2019 | 53 | 0.620 |
Why?
|
| Research Design | 2 | 2023 | 692 | 0.610 |
Why?
|
| Angiogenesis Inhibitors | 3 | 2015 | 205 | 0.590 |
Why?
|
| Therapies, Investigational | 1 | 2018 | 12 | 0.580 |
Why?
|
| Multiple Sclerosis | 2 | 2021 | 326 | 0.550 |
Why?
|
| Central Nervous System Neoplasms | 2 | 2024 | 197 | 0.550 |
Why?
|
| Ganglioglioma | 1 | 2016 | 22 | 0.520 |
Why?
|
| Hemangioendothelioma, Epithelioid | 1 | 2015 | 10 | 0.490 |
Why?
|
| Healthcare Disparities | 2 | 2022 | 432 | 0.480 |
Why?
|
| Blindness | 1 | 2015 | 70 | 0.470 |
Why?
|
| Magnetic Resonance Imaging | 10 | 2025 | 3560 | 0.460 |
Why?
|
| Antibodies, Monoclonal, Humanized | 3 | 2020 | 512 | 0.450 |
Why?
|
| Central Nervous System Diseases | 1 | 2014 | 107 | 0.430 |
Why?
|
| West Nile virus | 1 | 2015 | 117 | 0.420 |
Why?
|
| West Nile Fever | 1 | 2015 | 139 | 0.410 |
Why?
|
| Humans | 46 | 2025 | 124705 | 0.410 |
Why?
|
| Neovascularization, Pathologic | 1 | 2014 | 240 | 0.410 |
Why?
|
| Epilepsy | 1 | 2020 | 873 | 0.400 |
Why?
|
| Neuroimaging | 1 | 2015 | 339 | 0.380 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 3 | 2 | 2022 | 24 | 0.360 |
Why?
|
| Adult | 20 | 2025 | 29554 | 0.360 |
Why?
|
| Mutation | 7 | 2025 | 5845 | 0.350 |
Why?
|
| Neoplasms | 4 | 2019 | 2780 | 0.340 |
Why?
|
| Body Height | 2 | 2021 | 215 | 0.330 |
Why?
|
| Microtubule-Associated Proteins | 2 | 2022 | 245 | 0.330 |
Why?
|
| Aged | 15 | 2025 | 19830 | 0.320 |
Why?
|
| Middle Aged | 19 | 2025 | 26884 | 0.310 |
Why?
|
| Retrospective Studies | 15 | 2024 | 16263 | 0.290 |
Why?
|
| Electroencephalography | 3 | 2020 | 864 | 0.290 |
Why?
|
| Bevacizumab | 3 | 2017 | 63 | 0.290 |
Why?
|
| Female | 23 | 2025 | 66577 | 0.240 |
Why?
|
| Young Adult | 9 | 2021 | 9023 | 0.240 |
Why?
|
| Antineoplastic Agents | 1 | 2014 | 1695 | 0.240 |
Why?
|
| Combined Modality Therapy | 3 | 2019 | 1238 | 0.230 |
Why?
|
| Male | 20 | 2025 | 61317 | 0.230 |
Why?
|
| Biliary Tract Neoplasms | 1 | 2023 | 18 | 0.210 |
Why?
|
| Olivary Nucleus | 1 | 2022 | 10 | 0.200 |
Why?
|
| Cerebellar Nuclei | 1 | 2022 | 15 | 0.200 |
Why?
|
| Headache | 2 | 2020 | 107 | 0.200 |
Why?
|
| Hypertrophy | 1 | 2022 | 103 | 0.190 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2019 | 69 | 0.190 |
Why?
|
| Cholangiocarcinoma | 1 | 2023 | 105 | 0.190 |
Why?
|
| Bile Duct Neoplasms | 1 | 2023 | 107 | 0.190 |
Why?
|
| Radiotherapy | 2 | 2019 | 135 | 0.190 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2020 | 2093 | 0.190 |
Why?
|
| Ependymoma | 1 | 2022 | 125 | 0.180 |
Why?
|
| Melanoma | 2 | 2022 | 941 | 0.180 |
Why?
|
| Solitary Fibrous Tumors | 1 | 2021 | 7 | 0.180 |
Why?
|
| JC Virus | 1 | 2021 | 30 | 0.180 |
Why?
|
| Multiple Sclerosis, Relapsing-Remitting | 1 | 2021 | 33 | 0.180 |
Why?
|
| Skull Base Neoplasms | 1 | 2021 | 35 | 0.170 |
Why?
|
| Frontal Bone | 1 | 2020 | 16 | 0.170 |
Why?
|
| Aged, 80 and over | 7 | 2021 | 6584 | 0.170 |
Why?
|
| Survival Analysis | 3 | 2019 | 1504 | 0.170 |
Why?
|
| Gastrointestinal Stromal Tumors | 1 | 2019 | 20 | 0.160 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor Proteins | 1 | 2019 | 4 | 0.160 |
Why?
|
| Socioeconomic Factors | 2 | 2022 | 867 | 0.160 |
Why?
|
| Oncogene Fusion | 1 | 2019 | 22 | 0.160 |
Why?
|
| Karnofsky Performance Status | 1 | 2019 | 12 | 0.160 |
Why?
|
| Optic Nerve Glioma | 1 | 2019 | 21 | 0.160 |
Why?
|
| Optic Nerve Neoplasms | 1 | 2019 | 19 | 0.160 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2019 | 80 | 0.150 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2022 | 539 | 0.150 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2018 | 74 | 0.150 |
Why?
|
| Telomerase | 1 | 2019 | 160 | 0.150 |
Why?
|
| Endpoint Determination | 1 | 2018 | 56 | 0.150 |
Why?
|
| Insurance, Health | 1 | 2019 | 138 | 0.140 |
Why?
|
| Erdheim-Chester Disease | 1 | 2017 | 25 | 0.140 |
Why?
|
| Central Nervous System Vascular Malformations | 1 | 2017 | 17 | 0.140 |
Why?
|
| Cerebral Ventricle Neoplasms | 1 | 2017 | 16 | 0.140 |
Why?
|
| Hemangioma, Cavernous, Central Nervous System | 1 | 2017 | 16 | 0.140 |
Why?
|
| Third Ventricle | 1 | 2017 | 27 | 0.140 |
Why?
|
| Hemangioma, Cavernous | 1 | 2017 | 19 | 0.140 |
Why?
|
| Prognosis | 4 | 2019 | 4620 | 0.130 |
Why?
|
| Disease-Free Survival | 2 | 2016 | 898 | 0.130 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2018 | 117 | 0.130 |
Why?
|
| Neurosurgical Procedures | 1 | 2019 | 301 | 0.130 |
Why?
|
| Pandemics | 1 | 2024 | 1104 | 0.130 |
Why?
|
| Antigens, CD34 | 1 | 2016 | 108 | 0.130 |
Why?
|
| Spinal Cord | 1 | 2017 | 303 | 0.130 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2019 | 1052 | 0.130 |
Why?
|
| Gliosarcoma | 1 | 2015 | 10 | 0.130 |
Why?
|
| Survival Rate | 2 | 2018 | 2055 | 0.120 |
Why?
|
| Promoter Regions, Genetic | 1 | 2019 | 1330 | 0.120 |
Why?
|
| Embolization, Therapeutic | 1 | 2017 | 219 | 0.120 |
Why?
|
| Incidence | 3 | 2020 | 3115 | 0.120 |
Why?
|
| Treatment Outcome | 7 | 2019 | 12364 | 0.120 |
Why?
|
| Hydrocephalus | 1 | 2017 | 240 | 0.120 |
Why?
|
| Reproducibility of Results | 2 | 2018 | 2885 | 0.110 |
Why?
|
| DNA Copy Number Variations | 1 | 2019 | 949 | 0.110 |
Why?
|
| Nervous System Diseases | 1 | 2018 | 375 | 0.110 |
Why?
|
| Prospective Studies | 2 | 2021 | 6132 | 0.110 |
Why?
|
| Cohort Studies | 3 | 2021 | 4799 | 0.100 |
Why?
|
| Wound Healing | 1 | 2015 | 459 | 0.090 |
Why?
|
| Neoplasm Proteins | 1 | 2015 | 670 | 0.090 |
Why?
|
| Israel | 2 | 2021 | 45 | 0.090 |
Why?
|
| Time Factors | 3 | 2018 | 6323 | 0.090 |
Why?
|
| Risk Factors | 4 | 2021 | 10249 | 0.090 |
Why?
|
| Nerve Tissue Proteins | 1 | 2016 | 1113 | 0.080 |
Why?
|
| Lung Neoplasms | 1 | 2020 | 1660 | 0.080 |
Why?
|
| Antineoplastic Agents, Alkylating | 2 | 2021 | 101 | 0.080 |
Why?
|
| Adolescent | 4 | 2021 | 19221 | 0.080 |
Why?
|
| Follow-Up Studies | 3 | 2020 | 5154 | 0.060 |
Why?
|
| Age Factors | 2 | 2019 | 2807 | 0.050 |
Why?
|
| RNA-Binding Protein EWS | 1 | 2022 | 33 | 0.050 |
Why?
|
| Dogs | 1 | 2024 | 774 | 0.050 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2022 | 108 | 0.050 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2023 | 188 | 0.050 |
Why?
|
| Dimethyl Fumarate | 1 | 2021 | 11 | 0.050 |
Why?
|
| Rare Diseases | 1 | 2022 | 191 | 0.040 |
Why?
|
| Risk Assessment | 2 | 2020 | 3444 | 0.040 |
Why?
|
| Information Dissemination | 1 | 2022 | 185 | 0.040 |
Why?
|
| Referral and Consultation | 1 | 2024 | 538 | 0.040 |
Why?
|
| Chemoradiotherapy | 1 | 2021 | 105 | 0.040 |
Why?
|
| Machine Learning | 1 | 2022 | 251 | 0.040 |
Why?
|
| Patient Care Team | 1 | 2024 | 541 | 0.040 |
Why?
|
| Cranial Irradiation | 1 | 2020 | 67 | 0.040 |
Why?
|
| Pregnancy Trimester, Third | 1 | 2019 | 119 | 0.040 |
Why?
|
| Intralaminar Thalamic Nuclei | 1 | 2017 | 6 | 0.040 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2017 | 37 | 0.040 |
Why?
|
| Dura Mater | 1 | 2017 | 25 | 0.040 |
Why?
|
| Repressor Proteins | 1 | 2022 | 815 | 0.040 |
Why?
|
| Linear Models | 1 | 2019 | 682 | 0.040 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2017 | 163 | 0.030 |
Why?
|
| Vision Disorders | 1 | 2019 | 210 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 2018 | 354 | 0.030 |
Why?
|
| Immunosuppressive Agents | 1 | 2021 | 650 | 0.030 |
Why?
|
| Sex Factors | 1 | 2020 | 1287 | 0.030 |
Why?
|
| Immunologic Factors | 1 | 2018 | 175 | 0.030 |
Why?
|
| Tumor Microenvironment | 1 | 2020 | 556 | 0.030 |
Why?
|
| Macrophages | 1 | 2020 | 621 | 0.030 |
Why?
|
| Antigens, CD | 1 | 2017 | 431 | 0.030 |
Why?
|
| S100 Proteins | 1 | 2015 | 46 | 0.030 |
Why?
|
| Ki-67 Antigen | 1 | 2015 | 113 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2021 | 1562 | 0.030 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 2015 | 105 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2019 | 1113 | 0.030 |
Why?
|
| Pregnancy Complications | 1 | 2019 | 512 | 0.030 |
Why?
|
| ErbB Receptors | 1 | 2015 | 281 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2015 | 361 | 0.030 |
Why?
|
| Registries | 1 | 2020 | 1429 | 0.030 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2017 | 725 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2015 | 1326 | 0.020 |
Why?
|
| Disease Progression | 1 | 2017 | 2057 | 0.020 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2015 | 722 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2015 | 2043 | 0.020 |
Why?
|
| Electronic Health Records | 1 | 2015 | 722 | 0.020 |
Why?
|
| Pregnancy | 1 | 2019 | 7171 | 0.020 |
Why?
|
| Brain | 1 | 2017 | 2996 | 0.020 |
Why?
|
| Animals | 1 | 2024 | 34235 | 0.010 |
Why?
|